CN111712259A - Fcrn抗体及其使用方法 - Google Patents

Fcrn抗体及其使用方法 Download PDF

Info

Publication number
CN111712259A
CN111712259A CN201880089334.7A CN201880089334A CN111712259A CN 111712259 A CN111712259 A CN 111712259A CN 201880089334 A CN201880089334 A CN 201880089334A CN 111712259 A CN111712259 A CN 111712259A
Authority
CN
China
Prior art keywords
seq
sequence
antibody
cdr
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880089334.7A
Other languages
English (en)
Chinese (zh)
Inventor
L·E·凌
D·尼克斯
N·A·克利丰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Publication of CN111712259A publication Critical patent/CN111712259A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN201880089334.7A 2017-12-13 2018-12-13 Fcrn抗体及其使用方法 Pending CN111712259A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762598402P 2017-12-13 2017-12-13
US62/598402 2017-12-13
US201862701354P 2018-07-20 2018-07-20
US62/701354 2018-07-20
PCT/US2018/065568 WO2019118791A1 (en) 2017-12-13 2018-12-13 Fcrn antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
CN111712259A true CN111712259A (zh) 2020-09-25

Family

ID=65041911

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880089334.7A Pending CN111712259A (zh) 2017-12-13 2018-12-13 Fcrn抗体及其使用方法

Country Status (11)

Country Link
US (2) US11773168B2 (cg-RX-API-DMAC10.html)
EP (1) EP3723802A1 (cg-RX-API-DMAC10.html)
JP (3) JP7420720B2 (cg-RX-API-DMAC10.html)
KR (2) KR20260008175A (cg-RX-API-DMAC10.html)
CN (1) CN111712259A (cg-RX-API-DMAC10.html)
AU (1) AU2018386193B2 (cg-RX-API-DMAC10.html)
BR (1) BR112020011310A2 (cg-RX-API-DMAC10.html)
CA (1) CA3085751A1 (cg-RX-API-DMAC10.html)
IL (1) IL275070A (cg-RX-API-DMAC10.html)
SG (1) SG11202005021PA (cg-RX-API-DMAC10.html)
WO (1) WO2019118791A1 (cg-RX-API-DMAC10.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114129730A (zh) * 2021-09-16 2022-03-04 宁夏大学 FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用
WO2023030501A1 (zh) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
CN116782939A (zh) * 2020-11-06 2023-09-19 动量制药公司 FcRn抗体及其使用方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6853178B2 (ja) 2015-01-30 2021-03-31 モメンタ ファーマシューティカルズ インコーポレイテッド ＦｃＲｎ抗体およびその使用方法
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
JP7486437B2 (ja) 2018-06-08 2024-05-17 アルジェニクス ビーブイ 免疫性血小板減少症を治療する組成物及び方法
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
CA3148826A1 (en) * 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
ES2992247T3 (es) 2020-01-08 2024-12-11 argenx BV Antagonistas del receptor de Fc neonatal humano (FcRn) para el tratamiento de trastornos del pénfigo
CA3183153A1 (en) * 2020-06-17 2021-12-23 Christian HINDERER Compositions and methods for treatment of gene therapy patients
CA3200972A1 (en) * 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
MX2023012032A (es) * 2021-04-12 2023-12-08 Momenta Pharmaceuticals Inc Composiciones y métodos para tratar la miastenia gravis pediátrica.
MX2024007806A (es) * 2022-01-17 2024-07-04 argenx BV Metodos para tratar a pacientes con una enfermedad mediada por autoanticuerpos.
KR20250037789A (ko) 2022-06-15 2025-03-18 아르젠엑스 비브이 Fcrn/항원-결합 분자 및 사용 방법
US20250034260A1 (en) 2023-07-05 2025-01-30 Sanofi Fcrn antagonists for treatment of igg-related diseases and disorders
JP2026526949A (ja) 2023-07-31 2026-08-10 メディトックス インク． 抗体及びそれを含む免疫疾患治療用薬学的組成物
TW202527982A (zh) 2023-09-11 2025-07-16 美商默門塔醫藥公司 Fcrn抗體之醫藥組成物
WO2025186787A1 (en) * 2024-03-08 2025-09-12 Momenta Pharmaceuticals, Inc. Compositions and methods for treating fetal and neonatal alloimmune thrombocytopenia

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012167039A1 (en) * 2011-06-02 2012-12-06 Dyax Corp. Fc RECEPTOR BINDING PROTEINS
CN103717619A (zh) * 2011-05-25 2014-04-09 因内特制药股份有限公司 治疗发炎及自体免疫疾病之抗-kir抗体
WO2016123521A2 (en) * 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2016183352A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US7662928B2 (en) 2003-08-08 2010-02-16 The Research Foundation Of State University Of New York Anti-FcRn antibodies for treatment of auto/allo immune conditions
CA2534973A1 (en) 2003-08-08 2005-02-17 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatment of auto/allo immune conditions
CN101124245A (zh) 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
EP1865986B1 (en) 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
CA2637929A1 (en) 2006-01-25 2007-08-02 The Research Foundation Of State University Of New York Anti-fcrn antibodies for treatement of auto/allo immune conditions
WO2007104529A2 (en) 2006-03-13 2007-09-20 Ablynx N.V. Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
US8273351B2 (en) 2008-04-25 2012-09-25 Dyax Corp. Fc receptor binding proteins
CN102549016B (zh) 2009-06-30 2015-05-06 研究发展基金会 免疫球蛋白fc多肽
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
US20130323242A1 (en) 2012-06-01 2013-12-05 Ophthotech Corp. Compositions comprising an anti-pdgf aptamer and a vegf antagonist
US9844594B2 (en) 2012-12-18 2017-12-19 Merck Sharp & Dohme Corp. Liquid formulations for an anti-TNF α antibody
EP2991666B1 (en) 2013-05-02 2020-03-25 Momenta Pharmaceuticals, Inc. Sialylated glycoproteins
KR101815265B1 (ko) 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
EP4241852A3 (en) 2014-04-30 2023-11-15 Hanall Biopharma Co., Ltd. Antibody binding to fcrn for treating autoimmune diseases
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
JP6913527B2 (ja) 2017-06-22 2021-08-04 株式会社小松製作所 油圧ポンプおよびモータ
MA51032A (fr) 2017-12-08 2021-03-17 Argenx Bvba Utilisation d'antagonistes de fcrn pour le traitement de la myasthénie grave généralisée
BR112020011310A2 (pt) 2017-12-13 2020-11-17 Momenta Pharmaceuticals, Inc. anticorpos contra fcrn e seus métodos de uso
EP3762027A4 (en) 2018-02-13 2022-06-15 The Brigham & Women's Hospital, Inc. THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES
EA202190264A1 (ru) 2018-07-20 2021-05-20 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ АНТИТЕЛ ПРОТИВ FcRn
IL280280B2 (en) 2018-07-20 2024-11-01 Momenta Pharmaceuticals Inc Compositions of fcrn antibodies and methods of use thereof
JP7518821B2 (ja) 2018-10-16 2024-07-18 ユーシービー バイオファルマ エスアールエル 重症筋無力症の治療方法
CA3148826A1 (en) 2019-08-01 2021-02-04 Janssen Biotech, Inc. Fcrn antibodies and methods of use thereof
CA3200972A1 (en) 2020-11-06 2022-05-12 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103717619A (zh) * 2011-05-25 2014-04-09 因内特制药股份有限公司 治疗发炎及自体免疫疾病之抗-kir抗体
WO2012167039A1 (en) * 2011-06-02 2012-12-06 Dyax Corp. Fc RECEPTOR BINDING PROTEINS
WO2016123521A2 (en) * 2015-01-30 2016-08-04 Momenta Pharmaceuticals, Inc. Fcrn antibodies and methods of use thereof
WO2016183352A1 (en) * 2015-05-12 2016-11-17 Syntimmune, Inc. Humanized affinity matured anti-fcrn antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CONGLEI LI 等: "The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 121, no. 11, pages 4537 - 4547, XP002790138, DOI: 10.1172/JCI57850 *
尹立雪: "现代超声心脏电生理学", vol. 1, 30 November 2007, 科学技术文献出版社, pages: 733 *
秦丽丽: "现代妇产科疾病手术学", vol. 1, 科学技术文献出版社, pages: 172 *
邓晶 等: "与母源性HLA 抗体相关的新生儿同种免疫性血小板减少症", 中国输血杂志, vol. 29, no. 9, pages 935 - 937 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116782939A (zh) * 2020-11-06 2023-09-19 动量制药公司 FcRn抗体及其使用方法
WO2023030501A1 (zh) * 2021-09-03 2023-03-09 舒泰神（北京）生物制药股份有限公司 特异性识别FcRn的抗体及其应用
CN114129730A (zh) * 2021-09-16 2022-03-04 宁夏大学 FcRn抑制剂在制备降低炎症反应和/或防治结核病的试剂或药物中的应用

Also Published As

Publication number Publication date
US11773168B2 (en) 2023-10-03
AU2018386193A1 (en) 2020-06-25
BR112020011310A2 (pt) 2020-11-17
SG11202005021PA (en) 2020-07-29
JP7904366B2 (ja) 2026-08-12
KR102904658B1 (ko) 2025-12-29
AU2018386193A8 (en) 2020-07-02
US20240158509A1 (en) 2024-05-16
KR20260008175A (ko) 2026-01-15
US20220064290A1 (en) 2022-03-03
JP2021506786A (ja) 2021-02-22
EP3723802A1 (en) 2020-10-21
WO2019118791A1 (en) 2019-06-20
CA3085751A1 (en) 2019-06-20
AU2018386193B2 (en) 2025-04-24
NZ765250A (en) 2026-02-27
JP7420720B2 (ja) 2024-01-23
JP2024016042A (ja) 2024-02-06
JP7690538B2 (ja) 2025-06-10
JP2025143252A (ja) 2025-10-01
KR20200098604A (ko) 2020-08-20
IL275070A (en) 2020-07-30

Similar Documents

Publication Publication Date Title
JP7690538B2 (ja) ＦｃＲｎ抗体およびその使用方法
JP7442575B2 (ja) Ｆｃｒｎ抗体及びその使用方法
CN107567460B (zh) Fcrn抗体及其使用方法
HK40104376A (en) Fcrn antibodies and methods of use thereof
HK40002836A (en) Fcrn antibodies and methods of use thereof
HK40002836B (en) Fcrn antibodies and methods of use thereof
BR122025025099A2 (pt) Anticorpos contra fcrn, usos dos mesmos e composições

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: new jersey

Applicant after: MOMENTA PHARMACEUTICALS, Inc.

Address before: Massachusetts, USA

Applicant before: MOMENTA PHARMACEUTICALS, Inc.

Country or region before: U.S.A.